Cullinan Therapeutics, Inc.

NASDAQ:CGEM

Medical - Pharmaceuticals

Healthcare
$9.01 +4.29%

+$0.62 today

Market cap
$584.94M
Beta
0.01
P/E (TTM)
-4.0
EPS (TTM)
-$3.73
52W Low $5.68High $16.74

Volume 1.06M

Average 0.99M

CGEM Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Cullinan Therapeutics, Inc.NASDAQ: CGEM

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin not reported for Q1 FY2026

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
—— YoY
LTMMar 2026
—— YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2021
100.0%
Year-over-year change
—

Gross Margin vs competitors

How CGEM compares with its peers on the latest reported figures

CGEM Competitors Peer median
Gross Margin for CGEM and competitors
Company Period LTM level YoY 3-year change
IMTXImmatics N.V.LTM Mar 2026100.0% +0.1 pp+61.8 pp
ADCTADC Therapeutics S.A.LTM Mar 202690.7% -2.0 pp-7.9 pp
CGENCompugen Ltd.LTM Mar 202688.1% +17.9 pp+0.3 pp
NRIXNurix Therapeutics, Inc.LTM Aug 202686.5% +249.4 pp+455.2 pp
MGNXMacroGenics, Inc.LTM Mar 202669.9% +7.9 pp-24.0 pp
LEGNLegend Biotech CorporationLTM Sep 202657.0% -3.6 pp+16.2 pp
JANXJanux Therapeutics, Inc.LTM Mar 202654.1% +476.2 pp-10.5 pp
XNCRXencor, Inc.LTM Jun 202643.3% -18.0 pp+112.9 pp
CGEMCullinan Therapeutics, Inc.FY2025— ——
AVBPArriVent BioPharma, Inc. Common StockFY2025— ——
ALXOALX Oncology Holdings Inc.FY2025— ——
Peer median (excluding CGEM) 78.2%+4.0 pp+8.2 pp

Competitors are the stored peer set for CGEM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue18.94M0000
Cost of Revenue000306K0
Gross Profit18.94M00(306K)0
Gross Margin100.0%————
Research & Development57.75M91.95M148.16M142.9M187.4M
Selling, General & Admin29.15M40.19M42.49M53.71M54.25M
Operating Expenses86.9M(144.65M)191.09M196.61M241.65M
Depreciation & Amortization53K93K310K306K311K
EBITDA(67.43M)(132.04M)(190.34M)(167.15M)(219.57M)
EBITDA Margin-356.0%————
Operating Income(67.95M)144.65M(191.09M)(196.92M)(241.65M)
Operating Margin-358.7%————
Interest Income477K6.61M21.63M29.66M22.21M
Interest Expense00000
Other Income / Expenses469K6.67M21.87M29.46M21.77M
Income Before Tax(67.49M)151.32M(169.22M)(167.46M)(219.88M)
Pre-Tax Margin-356.3%————
Income Tax Expense042.12M(14.12M)117K0
Net Income(65.57M)111.21M(153.16M)(167.38M)(219.88M)
Net Margin-346.1%————
EPS (Basic)(1.48)2.46(3.69)(3.11)(3.72)
EPS (Diluted)(1.48)2.38(3.69)(3.11)(3.72)
Weighted Avg Shares44.29M45.16M41.51M53.77M59.05M
Weighted Avg Shares (Diluted)44.29M46.64M41.55M53.77M59.05M

Cullinan Therapeutics, Inc.

NASDAQ:CGEM

Intrinsic Alpha fair value

Locked

Current Price

$9.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.